No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

Petra J Woestenberg; Audrey J King; Marianne A B van der Sande; Robine Donken; Suzan Leussink; Fiona R M van der Klis; Christian J P A Hoebe; Johannes A Bogaards; Birgit H B van Benthem; Medical Microbiological Laboratories; Public Health Services

doi:10.1016/j.jinf.2017.01.007

No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

J Infect. 2017 Apr;74(4):393-400. doi: 10.1016/j.jinf.2017.01.007. Epub 2017 Jan 23.

Collaborators

D Adema¹⁰, R Buist-Arkema¹⁰, A Beerens¹⁰, D Luijt¹⁰, S Meijer¹⁰, J Schirm¹⁰, A Buiting¹¹, M Peeters¹¹, J Rossen¹¹, H Verbakel¹¹, P van Esch¹¹, J Verweij¹¹, A van der Eijk¹², R Huisman¹², C Kerkhof¹², H Korff¹², M Schutten¹², J Velzing¹², F Verduyn-Lunel¹³, S Lakbiach¹³, P van Rosmalen¹³, R Schuurman¹³, D Abma¹⁴, K Adams¹⁴, S Bruisten¹⁴, I Linde¹⁴, P Oostvogel¹⁴, C Touwen¹⁴, W Vermeulen¹⁴, A Brink¹⁵, J Nelissen¹⁵, P Wolffs¹⁵, N Duijvendijk¹⁶, P Schneeberger¹⁶, M Dinnissen-van Poppel¹⁷, W Melchers¹⁷, Y Poort¹⁷, M Hooghiemstra¹⁸, H Huisman¹⁸, J Weel¹⁸, H Bosch¹⁹, T de Haas¹⁹, R Kleinspenkelink¹⁹, I Polman¹⁹, T Smits¹⁹, P van Goor²⁰, M Wolfhagen²⁰, C de Mooij²¹, E van Koolwijk²¹, M Peters²¹, C Swanink²¹, R Tiemessen²¹, T van Zwet²¹, J Janssen²², M Pelsers²², W de Waal²³, G Aalfs²⁴, J Kiewiet²⁴, P Sanders²⁴, H van Buel-Bruins²⁵, C van Bokhoven-Rombouts²⁶, P Cornelissen²⁶, M Kersten²⁶, C van Ruitenbeek²⁶, I Molenaar²⁶, E Doorn¹³, L Masthoff¹³, E Pannekoek¹³, V Sigurdsson¹³, H Götz²⁷, M Illidge-Onder de Linden²⁷, M Mattijssen²⁷, J Stam²⁷, E Swaders²⁷, F de Groot²⁸, F Postma²⁸, E Brouwers²⁹, A Niekamp²⁹, M Smit²⁹, A Botraby³⁰, D Bukasa³⁰, C de Haan³⁰, P Hut-van Vliet³⁰, T Taconis³⁰, M de Graas³¹, I Hondelink³¹, C Kampman³¹, A Gelissen-Hansen³², I de Koning³², H van Kruchten³², M van de Pas³², H Fennema³³, T Heijman³³, A Hogewoning³³, A van Leeuwen³³, M van Rooijen³³, F Neienhuijsen³⁴, M Pelgrim³⁴

Affiliations

¹ Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands; School of Public Health and Primary Care, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Electronic address: [email protected].
² Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: [email protected].
³ Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands; Julius Center, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Electronic address: [email protected].
⁴ Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands; Department of Pathology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: [email protected].
⁵ Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: [email protected].
⁶ Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: [email protected].
⁷ School of Public Health and Primary Care, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands; Department of Sexual Health, Infectious Diseases and Environment, South Limburg Public Health Service, P.O. Box 2022, 6160 HA Geleen, The Netherlands. Electronic address: [email protected].
⁸ Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: [email protected].
⁹ Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: [email protected].
¹⁰ Certe, The Netherlands.
¹¹ ETZ Hospital Tilburg, The Netherlands.
¹² Erasmus Medical Center, The Netherlands.
¹³ University Medical Center Utrecht, The Netherlands.
¹⁴ Public Health Laboratory Amsterdam, The Netherlands.
¹⁵ Maastricht University Medical Center, The Netherlands.
¹⁶ Jeroen Bosch Hospital, The Netherlands.
¹⁷ Radboud University Medical Center, The Netherlands.
¹⁸ Izore, The Netherlands.
¹⁹ LabMicTA, The Netherlands.
²⁰ Isala, The Netherlands.
²¹ Rijnstate, The Netherlands.
²² Medical Laboratory Dr. Stein & College, The Netherlands.
²³ Canisius Wilhelmina Hospital, The Netherlands.
²⁴ PHS Drenthe, Germany.
²⁵ PHS IJsselland, The Netherlands.
²⁶ PHS Gelderland-Zuid, The Netherlands.
²⁷ PHS Rotterdam-Rijnmond, The Netherlands.
²⁸ PHS Groningen, The Netherlands.
²⁹ PHS Zuid Limburg, The Netherlands.
³⁰ PHS Fryslân, The Netherlands.
³¹ PHS Twente, The Netherlands.
³² PHS Hart voor Brabant, The Netherlands.
³³ PHS Amsterdam, The Netherlands.
³⁴ PHS Gelderland-Midden, The Netherlands.

PMID: 28126492
DOI: 10.1016/j.jinf.2017.01.007

Abstract

Objectives: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands.

Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior.

Results: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not change these results.

Conclusions: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW.

Keywords: Condylomata acuminata; Human papillomavirus 11; Human papillomavirus 6; Human papillomavirus vaccine, L1 type 16, 18; Prevention & control; Vaccination; Warts.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Ambulatory Care Facilities
Condylomata Acuminata / prevention & control*
Condylomata Acuminata / virology
Cross Protection*
Cross-Sectional Studies
Female
Human papillomavirus 11 / immunology*
Human papillomavirus 16 / immunology
Human papillomavirus 18 / immunology*
Human papillomavirus 6 / immunology
Humans
Netherlands / epidemiology
Papillomavirus Infections / epidemiology
Papillomavirus Infections / immunology
Papillomavirus Infections / prevention & control*
Papillomavirus Infections / virology
Papillomavirus Vaccines / immunology*
Prevalence
Sexually Transmitted Diseases / prevention & control
United Kingdom / epidemiology
Uterine Cervical Neoplasms / prevention & control
Vagina / virology
Young Adult

Substances

Papillomavirus Vaccines
human papillomavirus vaccine, L1 type 16, 18